They can be divided into two groups based on their effector functions: direct tumor-targeting mAbs, such as anti-CD20, anti-Her2, and anti-EGFR target the tumor directly through innate effectors, whereas immunomodulatory mAbs (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4, and anti-CD40) activate the adaptive immune system. The gene discussed is ERBB2; the disease is neoplasm.